Los Angeles, Aug. 27, 2014 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program™, announces the execution of an agreement with BioWyze, LLC. BioWyze provides expert solutions in the areas of product development and market penetration strategies to the biotech, pharma, medical device and clinical research industries. Beginning September 8, 2014, BioCorRx will be working directly with Jeff Bagshaw, Richard Maloy, Tobin Geatz, Jeff Reiniche, Vicky Robinson, and Grace Granato of BioWyze. "We look forward to this strategic relationship with the BioWyze team. BioCorRx can benefit greatly from their expertise with many well-respected corporations in a wide variety of fields and specialties, " states BioCorRx, Inc. CEO Kent Emry.
Jeff Bagshaw serves as Managing Partner at BioWyze, with over 25 years of experience in various medical fields including the clinical development, sales, marketing and commercialization of products over multiple therapeutic areas. Mr. Bagshaw has held multiple Senior Executive leadership roles in both sales and marketing including Chief Operating Officer, Senior Vice President of Medical Marketing and Compliance, and Senior Vice President of Sales and Marketing at Inclinix, Inc. His experience also includes leadership roles at Hoffman La Roche, Bristol Myers Squibb and Exact Sciences. "BioCorRx is entering an exciting growth phase of its business, and we are honored to have been selected by the leadership team to support their strategic corporate goals. Initially, our efforts will focus on establishing scalable business processes while optimizing current business. Supporting our licensees' expansion within their served market is a priority and will be an important function moving forward, as will be the identification of other expansion verticals along with the development of technology solutions," states Jeff Bagshaw, BioWyze Managing Partner.
Richard Maloy serves as Principle at BioWyze and has over 20 years of experience and documented results in managed markets/trade, category/brand management and sales for the world's top pharmaceutical companies. Most recently, Richard contributed to the development of Warner Chilcott (formerly Procter and Gamble Rx Pharmaceuticals).
Tobin Geatz serves as Principle at BioWyze. He has served as CEO of five private companies, VP of a NASDAQ public company, CEO and Chairman of the Board of Inclinix, Inc., was founder and Chairman of the Board of PharmaTech Solutions, as well as made Special General Partner at Aurora Funds II. Tobin, who holds nine patents in the field of Chemistry, has also founded, funded and operated several companies including Applied Chemical Solutions, Supercritical Systems, and Discrete Wireless.
Jeff Reiniche, C.P.A. has founded, funded and operated Health Alliance, Inc., DeliverMed, Inc., and Priva-Technologies, Inc. Jeff has advisory experience with large corporations such as Nike, Simmons Mattress Inc., and Warnaco, Inc. He has held multiple executive positions including CFO of Click Commerce, Inc., CFO of Inclinix, Inc., and Controller of The Virgoro Corporation.
Vicky Robinson serves as Principal at BioWyze where she draws on 13 years of experience in operationalizing processes and strategies, scaling teams and service offerings, and delivering unparalleled customer service. She most recently held the role as Executive Director of Project Management for Inclinix, Inc.
Grace Granato brings her Clinical Outcomes and Informatics experience to the BioWyze team. Grace has over a decade of experience as a Clinical Applications Analyst, Training Specialist and Nurse Educator, serving the healthcare network.
Visit BioCorRx, Inc.'s new investor relations website www.BICXcorp.com to receive the most up-to-date company information.
About BioCorRx, Inc.
BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment and rehabilitation company on the leading edge of substance abuse addiction treatment. The company has developed a highly effective program called the Start Fresh Program™ consisting of two components used by various addiction clinics in the US. Clinic reports show that the treatment program has an extremely high success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one-on-one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations SmallCapVoice.com, Inc. 512-267-2430